My name is Erica. I have Friedreich’s Ataxia but that is not my only defining quality. I am also married, thirty-one, and a mother to a five-year-old girl, four-year-old boy and one-year-old boy. The path I have chosen in life is hard, but it is also rewarding. I like to...
The Collaborative clinical research network on Friedreich’s ataxia from Montreal is now seeking the participation of a pediatric patient with a diagnosis of Freidreich’s ataxia in order to join the study of natural history! This international network brings together 13 sites working together to advance the treatment and clinical...
Late-onset hereditary dominant episodic ataxia in French Canadians Dr David Pellerin 1, Dr. Mathilde Renaud 2, Mrs. Karine Choquet 1, Prof. Martine Tétreault 3, Mrs. Sylvie Provost 3, Mrs. Marie-Josée Dicaire 1, Dr Roberta La Piana 1, Dr Rami Massie 1, Dr Colin Chalk 1, Dr. Anne-Louise Lafontaine 1, Prof. Marie-Pierre...
Gene editing of human hematopoietic stem and progenitor cells for Friedreich’s ataxia using CRISPR/Cas9 technology Dr. Celine Rocca 1, Ms. Shi Yanmeng 1, Mr. Jay Sharma 1, Dr. Prashant Mali 1, Dr. Stephanie Cherqui 1 University of California, San Diego Our goal is now to develop an autologous HSPC...
Friedreich Ataxia Collaborative Clinical Research Network and Natural History Research Project We want to inform you that Dr. Antoine Duquette, a neurologist at the CHUM, and his research team will now be responsible for a site in Montreal that integrates the Collaborative Research Network in Friedreich Ataxia (CCRN in FA)...
ACHIEVED PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT IMPROVEMENT IN MFARS COMPARED TO PLACEBO AFTER 48 WEEKS OF TREATMENT Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, announced today that the registrational Part 2 portion of the MOXIe Phase 2 trial of omaveloxolone in patients with Friedreich’s ataxia (FA) met its...
Mataró, Barcelona, Spain and Charleroi, Belgium, October 8, 2019 – Minoryx Therapeutics, a company specializing in the development of innovative treatments for orphan central nervous system (CNS) diseases, today announces that it has completed recruitment in the FRAMES phase 2 clinical trial of its novel PPARγ agonist, leriglitazone (MIN-102), in patients...